Treatment of sjogren's disease with nuclease fusion proteins
AssigneeResolve Therapeutics, LLC
InventorsJames Arthur Posada, Daniel BURGE
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating Sjogren's disease by administering nuclease fusion proteins. The methods of the disclosure are useful to treat symptoms associated with Sjogren's disease, including fatigue.
Claims106
A method for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the method comprising administering an effective amount of an RNase-Fc fusion protein to the patient, thereby treating Sjogren's disease by reducing fatigue in the patient.
A method for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the method comprising administering by intravenous injection a dose of an RNase-Fc fusion protein of about 5-10 mg/kg to the patient, thereby treating Sjogren's disease by reducing fatigue in the patient.
A method for treating Sjogren's disease by improving cognitive effects in a human patient in need thereof, the method comprising administering an effective amount of an RNase-Fc fusion protein to the patient, thereby treating Sjogren's disease by improving cognitive effects in the patient.
A method for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the method comprising administering an effective amount of an RNase-Fc fusion protein comprising the amino acid sequence as set forth in SEQ ID NO:
- 50 to the patient, thereby treating Sjogren's disease by reducing fatigue in the patient.
A method for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, comprising administering an effective amount of a pharmaceutical composition to the patient, wherein the composition comprises:
- an RNase-Fc fusion protein comprising the amino acid sequence as set forth in SEQ ID NO:
- 50;
- and one or more pharmaceutically acceptable carriers and/or diluents, thereby treating Sjogren's disease by reducing fatigue in the patient.
A kit comprising a container comprising an injectable solution and instructions for use in treating Sjogren's disease by reducing fatigue in a human patient in need thereof, comprising:
- an effective amount of an RNase-Fc fusion protein as set forth in SEQ ID NO:
- 50;
- and
- one or more pharmaceutically acceptable carriers and/or diluents;
- wherein the injectable solution is formulated for intravenous administration.
An RNase-Fc fusion protein for use in method for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the treatment comprising administering an effective amount of an RNase-Fc fusion protein to the patient.
Use of an RNase-Fc fusion protein for use in the manufacture of a medicament for treating Sjogren's disease by reducing fatigue in a human patient in need thereof.
An RNase-Fc fusion protein for use in a method for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the treatment comprising administering by intravenous injection a dose of an RNase-Fc fusion protein of about 5-10 mg/kg to the patient.
Use of an RNase-Fc fusion protein for use in the manufacture of a medicament for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the use comprising administering by intravenous injection a dose of an RNase-Fc fusion protein of about 5-10 mg/kg to the patient.
An RNase-Fc fusion protein for use in a method for treating Sjogren's disease by improving cognitive effects in a human patient in need thereof, the treatment comprising administering an effective amount of an RNase-Fc fusion protein to the patient.
Use of an RNase-Fc fusion protein for use in the manufacture of a medicament for treating Sjogren's disease by improving cognitive effects in a human patient in need thereof, the use comprising administering an effective amount of an RNase-Fc fusion protein to the patient.
An RNase-Fc fusion protein for use in a method for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the treatment comprising administering an effective amount of an RNase-Fc fusion protein comprising the amino acid sequence as set forth in SEQ ID NO:
- 50 to the patient.
Use of an RNase-Fc fusion protein for use in the manufacture of a medicament for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the use comprising administering an effective amount of an RNase-Fc fusion protein comprising the amino acid sequence as set forth in SEQ ID NO:
- 50 to the patient.
An RNase-Fc fusion protein for use in a method for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the treatment comprising administering an effective amount of a pharmaceutical composition to the patient, wherein the composition comprises:
- an RNase-Fc fusion protein comprising the amino acid sequence as set forth in SEQ ID NO:
- 50;
- and one or more pharmaceutically acceptable carriers and/or diluents.
An RNase-Fc fusion protein for use in the manufacture of a medicament for treating Sjogren's disease by reducing fatigue in a human patient in need thereof, the use comprising administering an effective amount of a pharmaceutical composition to the patient, wherein the composition comprises:
- an RNase-Fc fusion protein comprising the amino acid sequence as set forth in SEQ ID NO:
- 50;
- and one or more pharmaceutically acceptable carriers and/or diluents.
A method of treating Sjogren's disease in a patient in need thereof, the method comprising administering an effective amount of an RNA nuclease agent to the patient, wherein treatment results in a decrease in one or more inflammatory-related genes.
A method of treating Sjogren's disease in a patient in need thereof, the method comprising administering an effective amount of an RNA nuclease agent to the patient, wherein treatment results in increase in one or more inflammatory-related genes.
A method of treating Sjogren's disease in a patient in need thereof, the method comprising administering an effective amount of an RNA nuclease agent to the patient, wherein treatment results in an increase in one or more cytokines and an improvement in fatigue.
A method of identifying a patient having Sjogren's disease as a candidate for treatment with an RNA nuclease agent, comprising:
- (a) determining an inflammatory-related gene expression profile in a sample obtained from the patient;
- and
- (b) comparing the inflammatory-related gene expression profile determined in step (a) with an inflammatory-related gene expression profile in a sample obtained from a suitable control subject,
- wherein the inflammatory-related gene expression profile indicates that the patient is a candidate for treatment with an RNA nuclease agent.
Use of an RNA nuclease agent in the manufacture of a medicament for the treatment of Sjogren's disease, the use comprising administering an effective amount of an RNA nuclease agent to the patient wherein treatment results in a decrease in one or more inflammatory-related genes.
An RNA nuclease agent for use in a method of treating Sjogren's disease, the use comprising administering an effective amount of an RNA nuclease agent to the patient wherein treatment results in a decrease in one or more inflammatory-related genes.
Use of an RNA nuclease agent in the manufacture of a medicament for the treatment of Sjogren's disease, the use comprising administering an effective amount of an RNA nuclease agent to the patient, wherein treatment results in increase in one or more inflammatory-related genes.
An RNA nuclease agent for use in a method of treating Sjogren's disease, the use comprising administering an effective amount of an RNA nuclease agent to the patient, wherein treatment results in increase in one or more inflammatory-related genes.
Use of an RNA nuclease agent in the manufacture of a medicament for the treatment of Sjogren's disease, the use comprising administering an effective amount of an RNA nuclease agent to the patient, wherein treatment results in an increase in one or more cytokines and an improvement in fatigue.
An RNA nuclease agent for use in a method of treating Sjogren's disease, the use comprising administering an effective amount of an RNA nuclease agent to the patient, wherein treatment results in an increase in one or more cytokines and an improvement in fatigue.
Dependencies are inferred from the claim text.